Company intelligence / Profile preview
Kailera Therapeutics
Waltham, Massachusetts, USAkailera.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Kailera’s lead asset KAI‑9531 (injectable GLP‑1/GIP dual agonist) has shown positive results in Phase 2 trials for obesity and type 2 diabetes conducted in China. The company’s pipeline includes both injectable and oral therapies targeting metabolic diseases. All programs were acquired ex-Greater China from Jiangsu Hengrui Pharmaceuticals.
- Therapeutic areas
- Endocrinology
- Modalities
- Injectable peptides (GLP-1/GIP dual agonist, GLP-1/GIP/glucagon triagonist)Oral small molecules (GLP‑1 receptor agonist)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Jiangsu Hengrui Pharmaceuticals Co., Ltd. – exclusive global development and commercialization rights to four metabolic disease assets outside Greater China.Atlas Venture, Bain Capital Life Sciences, RTW Investments – major investors/co-leads of Series A financing.Lyra Capital – investor.
Beyond the preview
Go deeper on Kailera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kailera Therapeutics.